Joel E Sutton

US Patent:

57634939, Jun 9, 1998

Filed:

Jun 21, 1996

Appl. No.:

8/667239

Inventors:

Michael D. Ruff - Greenville NC
Joel Elmore Sutton - Greenville NC

Assignee:

Glaxo Wellcome Inc. - Research Triangle Park NC

International Classification:

A01N 3718
A61K 31165

US Classification:

514617

Abstract:

This application discloses a method of inhibiting degradation of the antidepressant bupropion hydrochloride in a solid pharmaceutical formulation, so that the pharmaceutical formulation will maintain at least 80% of its initial bupropion potency after one year.

US Patent:

50987151, Mar 24, 1992

Filed:

Dec 20, 1990

Appl. No.:

7/631741

Inventors:

Terrance T. McCabe - Durham NC
Robert A. Stagner - Greenville NC
Joel E. Sutton - Greenville NC

Assignee:

Burroughs Wellcome Co. - Research Triangle Park NC

International Classification:

A61K 936

US Classification:

424479

Abstract:

The invention comprises a flavored thin film coating on solid oral dosage pharmaceutical tablets containing unpleasant tasting ingredients such as triprolidine hydrochloride and pseudoephedrine hydrochloride. The flavored coating of the invention is comprised of a film-forming substance such as a hydroxypropyl methylcellulose and a polyethylene glycol, a sweetening agent and a flavoring agent. The method of the invention comprises aqueous spray-coating of the flavored sweetened coating onto the pharmaceutical tablets.

US Patent:

54277981, Jun 27, 1995

Filed:

Aug 12, 1993

Appl. No.:

8/105447

Inventors:

Jennie Sue G. Ludwig - Greenville NC
William L. Bass - Farmville NC
Joel E. Sutton - Greenville NC

Assignee:

Burroughs Wellcome Co. - Research Triangle Park NC

International Classification:

A61K 922

US Classification:

424464

Abstract:

A controlled sustained release tablet having at least one year shelf life and containing bupropion hydrochloride, hydroxypropyl methylcellulose and cysteine hydrochloride or glycine hydrochloride with the tablet having a surface area to volume ratio to effectively control bupropion hydrochloride release in the body.

US Patent:

53589700, Oct 25, 1994

Filed:

Aug 12, 1993

Appl. No.:

8/105437

Inventors:

Michael D. Ruff - Greenville NC
Sanyasi R. Kalidindi - Edison NJ
Joel E. Sutton - Greenville NC

Assignee:

Burroughs Wellcome Co. - Research Triangle Park NC

International Classification:

A61K 31135

US Classification:

514649

Abstract:

This application discloses a method of inhibiting degradation of the antidepressant bupropion hydrochloride in a solid pharmaceutical formulation, so that the pharmaceutical formulation will maintain at least 80% of its initial bupropion potency after one year.

US Patent:

55412319, Jul 30, 1996

Filed:

Aug 25, 1994

Appl. No.:

8/296252

Inventors:

Michael D. Ruff - Greenville NC
Joel E. Sutton - Greenville NC

Assignee:

Glaxo Wellcome Inc. - Research Triangle Park NC

International Classification:

A61K 31135

US Classification:

514649

Abstract:

This application discloses a method of inhibiting degradation of the antidepressant bupropion hydrochloride in a solid pharmaceutical formulation, so that the pharmaceutical formulation will maintain at least 80% of its initial bupropion potency after one year.

US Patent:

57310009, Mar 24, 1998

Filed:

Mar 22, 1996

Appl. No.:

8/586916

Inventors:

Michael David Ruff - Greenville NC
Sanyasi Raju Kalidindi - Edison NJ
Joel Elmore Sutton - Greenville NC

Assignee:

Glaxo Wellcome Inc. - Rtp NC

International Classification:

A61K 948

US Classification:

424451

Abstract:

This application discloses a method of inhibiting degradation of the antidepressant bupropion hydrochloride in a solid pharmaceutical formulation, so that the pharmaceutical formulation will maintain at least 80% of its initial bupropion potency after one year.